The KCNN1 antibody targets the KCNN1 protein, a member of the small-conductance calcium-activated potassium (SK) channel family. Encoded by the *KCNN1* gene, this channel is characterized by its calcium sensitivity mediated through calmodulin binding. KCNN1 (also known as SK1) regulates neuronal excitability and muscle contractility by contributing to the afterhyperpolarization phase of action potentials, thereby modulating cellular repolarization and firing frequency. It is predominantly expressed in the central nervous system, smooth muscle, and specific endocrine cells, playing roles in processes such as synaptic plasticity, vasodilation, and hormone secretion.
Antibodies against KCNN1 are essential tools in neuroscience and physiology research. They enable the detection, localization, and quantification of KCNN1 protein in tissues or cell lines using techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate KCNN1's distribution, expression patterns, and functional interactions in health and disease. Dysregulation of SK channels, including KCNN1. has been implicated in neurological disorders (e.g., epilepsy, ataxia), cardiovascular diseases, and metabolic syndromes. Researchers also employ KCNN1 antibodies to study channel modulation by pharmacological agents, aiding drug discovery for conditions linked to SK channel dysfunction. Validation via knockout controls or peptide-blocking assays ensures specificity, critical for reliable experimental outcomes.